Clinical Trial Update: A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for V591 COVID-19 vaccine in healthy participants (Phase 1/2) terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronavirus Disease

Drugs mentioned

• V591

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Coronavirus Disease (COVID-19) | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2021-12-23